SHIRE EXTENDS FOSRENOL PROGRAM

Published Online: Sunday, April 1, 2007

In an effort to help seniors impacted by the "doughnut hole," Shire Pharmaceuticals is launching a new Medicare Part D component under the Fosrenol (lanthanum carbonate) At Hand Patient Assistance Program.

Shire provides help to patients who have no coverage for Fosrenol under prescription drug benefits, Medicare, Medicaid, or other state-funded programs, by providing the drug free of charge or at a shared (reduced) cost. Now, qualifying patients enrolled in a Medicare Part D program who cannot afford their copayments or coinsurance, along with those facing the doughnut-hole coverage gap, may receive the drug at no cost. Patients will receive a monthly supply of Fosrenol through the end of the calendar year in which they enroll in the program.

Fosrenol is indicated to reduce serum phosphate in patients with end-stage renal disease. For more information about the program, call 866-325-8223.




Latest Articles
An Arkansas family is taking legal action against a pharmacy for dispensing the wrong medication to a 4-year-old child.
Pharmacists know that a cough can be triggered by many stimuli.
A Super Bowl 50 commercial may be encouraging patients to seek help for their constipation.
The FDA has accepted for review Otsuka and Lundbeck’s supplemental new drug application for a label update to brexipiprazole.
Latest Issues
$auto_registration$
VSEO N/A